

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$2.34
Change (%)	▲ 0.07 (3.08%)
Volume	64,392
52 Week Low	\$2.13
Market Cap	\$21,797,065
Rolling EPS	-4.20
PE Ratio	N/A
Shares Outstanding	9,314,985

Data as of 07/20/18 4:00 p.m. ET



Recent Headlines & Events

07/05/18 - 4:05 p.m.
Fibrocell Announces Closing of \$4.0 Million Registered Direct Offering

07/02/18 - 9:01 a.m.
Fibrocell Announces \$4.0 Million Registered Direct Offering Priced At-the-Market

There are currently no events scheduled.

05/31/18 - 4:05 p.m.
 Fibrocell Announces Closing of \$6.0 Million
 Registered Direct Offering

SEC Filings

Filing Date	Form
07/17/18	D
07/11/18	SC 13G
07/05/18	8-K
07/05/18	424B5

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	40	12.37	48.3	4,496,354
Mutual Fund	10	.37	1.5	137,493
Director and Officer	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	1,653,483	17.8	0	03/31/18
Sabby Management, LLC	679,408	7.3	679,408	05/29/18
Anson Funds Management LP.	679,408	7.3	679,408	05/29/18
Heights Capital Management, Inc.	679,408	7.3	679,408	05/29/18
Intracoastal Capital, L.L.C.	335,466	3.6	335,466	07/11/18
MSD Partners, L.P.	138,592	1.5	0	03/31/18
Point72 Asset Management, L.P.	80,000	0.9	40,000	03/31/18
The Vanguard Group, Inc.	74,729	0.8	21,273	03/31/18
Creative Planning, Inc.	37,202	0.4	14,984	06/30/18
Renaissance Technologies LLC	23,539	0.3	-2,220	03/31/18

Data provided by Nasdaq. Minimum 15 minutes delayed.